NDAORALTABLET, EXTENDED RELEASE
Approved
Mar 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
CLARINEX D 24 HOUR (desloratadine; pseudoephedrine sulfate) by Merck & Co. is long-acting tricyclic histamine antagonist with selective h 1 -receptor histamine antagonist activity. First approved in 2005.
Drug data last refreshed Yesterday · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLARINEX D 24 HOUR is an oral extended-release combination tablet containing desloratadine (a selective H1-receptor antagonist) and pseudoephedrine sulfate (a decongestant). It is indicated for allergic rhinitis symptoms including nasal congestion, sneezing, and itching. The desloratadine component provides long-acting histamine antagonism without significant CNS penetration, while pseudoephedrine addresses nasal airway obstruction.
LOE Approaching
As a maturing product approaching loss of exclusivity with moderate competitive pressure (30/100), brand teams face resource constraints and a shift toward cost-containment and lifecycle extension strategies rather than growth investments.
Mechanism of Action
long-acting tricyclic histamine antagonist with selective H 1 -receptor histamine antagonist activity. Receptor binding data indicates that at a concentration of 2 to 3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H 1 -receptor. Desloratadine inhibited…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on CLARINEX D 24 HOUR in a LOE-approaching phase offers limited growth trajectory but strong opportunity to develop expertise in lifecycle management, generic defense, and managed care negotiation. Professionals on this product should prioritize visibility into pipeline assets and cross-functional projects to position for advancement before team consolidation.
Brand Manager
Worked on CLARINEX D 24 HOUR at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.